Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Department of Pediatric Critical Care, Norton Children's Hospital/University of Louisville, Louisville, KY, USA.
Perfusion. 2021 May;36(4):407-414. doi: 10.1177/0267659120952979. Epub 2020 Aug 29.
The Pediatric Extracorporeal Membrane Oxygenation Prediction (PEP) model was created to provide risk stratification for all pediatric patients requiring extracorporeal life support (ECLS). Our purpose was to externally validate the model using contemporaneous cases submitted to the Extracorporeal Life Support Organization (ELSO) registry.
This multicenter, retrospective analysis included pediatric patients (<19 years) during their initial ECLS run for all indications between January 2012 and September 2014. Median values from the BATE dataset for activated partial thromboplastin time and internationalized normalized ratio were used as surrogates as these were missing in the ELSO group. Model discrimination was evaluated using area under the receiver operating characteristic curve (AUC), and goodness-of-fit was evaluated using the Hosmer-Lemeshow test.
A total of 4,342 patients in the ELSO registry were compared to 514 subjects from the bleeding and thrombosis on extracorporeal membrane oxygenation (BATE) dataset used to develop the PEP model. Overall mortality was similar (42% ELSO vs. 45% BATE). The c-statistic after external validation decreased from 0.75 to 0.64 and model calibration decreases most in the highest risk deciles.
Discrimination of the PEP model remains modest after external validation using the largest pediatric ECLS cohort. While the model overestimates mortality for the highest risk patients, it remains the only prediction model applicable to both neonates and pediatric patients who require ECLS for any indication and thus maintains potential for application in research and quality benchmarking.
儿科体外膜肺氧合预测(PEP)模型旨在为所有需要体外生命支持(ECLS)的儿科患者提供风险分层。我们的目的是使用提交给体外生命支持组织(ELSO)登记处的同期病例对该模型进行外部验证。
这项多中心回顾性分析纳入了 2012 年 1 月至 2014 年 9 月期间所有适应证的初始 ECLS 运行期间的<19 岁儿科患者。ELSO 组中缺少 BATE 数据集的活化部分凝血活酶时间和国际标准化比值的中位数值,因此将其用作替代值。使用接收者操作特征曲线(ROC)下面积(AUC)评估模型区分度,并使用 Hosmer-Lemeshow 检验评估拟合优度。
ELSO 登记处共有 4342 例患者与用于开发 PEP 模型的体外膜氧合出血和血栓形成(BATE)数据集的 514 例患者进行了比较。总体死亡率相似(ELSO 组为 42%,BATE 组为 45%)。外部验证后的 C 统计量从 0.75 降至 0.64,且模型校准度在风险最高的十分位数中下降最大。
使用最大的儿科 ECLS 队列进行外部验证后,PEP 模型的区分度仍然不高。虽然该模型对最高风险患者的死亡率高估,但它仍然是唯一适用于任何适应证需要 ECLS 的新生儿和儿科患者的预测模型,因此仍然具有在研究和质量基准测试中应用的潜力。